RAYMOND W COHEN
CIK 1258288 · Chief Executive Officer · last filed 2026-06-18
RAYMOND W COHEN is a Chief Executive Officer who has filed 77 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for RXST, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$38.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.93M
7
77
-$38.12M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RXST | Director | 66,532 | $6.96 | $462.7K | $0 | 2 | 2026-06-18 |
| KMTS | Director | 50,903 | $28.02 | $1.43M | $488.8K | 3 | 2026-03-30 |
| NSPR | Director | 92,417 | $0.82 | $75.8K | $0 | 1 | 2026-01-16 |
| Axonics, Inc. (AXNX) Delisted | Chief Executive Officer | 692,151 | $70.98 | $49.13M | -$36.75M | 27 | 2024-11-15 |
| BLFS | Director | 27,763 | $34.79 | $965.9K | -$1.69M | 21 | 2021-07-14 |
| SPECTRUM PHARMACEUTICALS INC (SPPI) Delisted | Director | 53,850 | $1.03 | $55.5K | -$169.9K | 11 | 2019-06-21 |
| Cardiac Science CORP (CSCX) Delisted | Director | 13,825 | — | — | $0 | 4 | 2009-05-27 |
Recent Filings
77 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | RXST | Grant (A) | +30,864 | $0 | EDGAR |
| 2026-03-30 | KMTS | Buy (P) | +10,000 | $199.8K | EDGAR |
| 2026-01-16 | NSPR | Grant (A) | +44,030 | $0 | EDGAR |
| 2025-09-08 | KMTS | Mixed | +27,909 | $289.0K | EDGAR |
| 2025-08-04 | RXST | Grant (A) | +35,668 | $0 | EDGAR |
| 2025-07-24 | KMTS | Grant (A) | +12,994 | $0 | EDGAR |
| 2024-11-15 | Axonics, Inc. (AXNX) Delisted | Disp (D) | −292,731 | -$20.78M | EDGAR |
| 2024-07-25 | Axonics, Inc. (AXNX) Delisted | Exer (M) | +103,896 | $2.38M | EDGAR |
| 2024-02-02 | Axonics, Inc. (AXNX) Delisted | Mixed | +28,239 | -$2.38M | EDGAR |
| 2023-02-02 | Axonics, Inc. (AXNX) Delisted | Mixed | +51,697 | -$1.90M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.